HEART TRANSPLANTATION Pediatric Recipients ISHLT 2005 J Heart

HEART TRANSPLANTATION Pediatric Recipients ISHLT 2005 J Heart Lung Transplant 2005; 24: 945 -982

Number of Transplants AGE DISTRIBUTION OF PEDIATRIC HEART RECIPIENTS (Transplants: January 1996 - June 2004) ISHLT 2005 J Heart Lung Transplant 2005; 24: 945 -982

AGE DISTRIBUTION FOR DONORS OF PEDIATRIC HEART RECIPIENTS Number of Transplants (Transplants: January 1996 - June 2004) ISHLT 2005 J Heart Lung Transplant 2005; 24: 945 -982

AGE DISTRIBUTION OF PEDIATRIC HEART RECIPIENTS By Year of Transplant Number of Transplants 355 ISHLT 2005 J Heart Lung Transplant 2005; 24: 945 -982

Number of Pediatric Cases Reporting NUMBER OF CENTERS REPORTING PEDIATRIC HEART TRANSPLANTS ISHLT 2005 J Heart Lung Transplant 2005; 24: 945 -982

DIAGNOSIS IN PEDIATRIC HEART TRANSPLANT RECIPIENTS (Age: < 1 Year) 1/1996 -6/2004 % of Cases 1988 -1995 ISHLT 2005 J Heart Lung Transplant 2005; 24: 945 -982

DIAGNOSIS IN PEDIATRIC HEART TRANSPLANT RECIPIENTS (Age: 1 -10 Years) 1/1996 -6/2004 % of Cases 1988 -1995 ISHLT 2005 J Heart Lung Transplant 2005; 24: 945 -982

DIAGNOSIS IN PEDIATRIC HEART TRANSPLANT RECIPIENTS (Age: 11 -17 Years) 1/1996 -6/2004 % of Cases 1988 -1995 ISHLT 2005 J Heart Lung Transplant 2005; 24: 945 -982

Survival (%) PEDIATRIC HEART TRANSPLANTATION Kaplan-Meier Survival (1/1982 -6/2003) ISHLT 2005 J Heart Lung Transplant 2005; 24: 945 -982

Survival (%) PEDIATRIC HEART TRANSPLANTATION Conditional Kaplan-Meier Survival (1/1982 -6/2003) ISHLT 2005 J Heart Lung Transplant 2005; 24: 945 -982

PEDIATRIC HEART TRANSPLANTATION Survival (%) Conditional 5 -year Kaplan-Meier Survival (1/1982 -6/2003) ISHLT 2005 J Heart Lung Transplant 2005; 24: 945 -982

PEDIATRIC HEART TRANSPLANTATION Conditional Kaplan-Meier Survival for Recent Era Survival (%) (1/1999 -6/2003) ISHLT 2005 J Heart Lung Transplant 2005; 24: 945 -982

Survival (%) PEDIATRIC HEART TRANSPLANTATION Kaplan-Meier Survival by Era (1/1982 -6/2003) ISHLT 2005 J Heart Lung Transplant 2005; 24: 945 -982

PEDIATRIC HEART TRANSPLANTATION Kaplan-Meier Survival by Era (1/1982 -6/2003) Survival (%) Age: < 1 Year ISHLT 2005 J Heart Lung Transplant 2005; 24: 945 -982

PEDIATRIC HEART TRANSPLANTATION Kaplan-Meier Survival by Era (1/1982 -6/2003) Survival (%) Age: 1 -10 Years ISHLT 2005 J Heart Lung Transplant 2005; 24: 945 -982

PEDIATRIC HEART TRANSPLANTATION Kaplan-Meier Survival by Era (1/1982 -6/2003) Survival (%) Age: 11 -17 Years ISHLT 2005 J Heart Lung Transplant 2005; 24: 945 -982

PEDIATRIC HEART TRANSPLANTATION Kaplan-Meier Survival Based on Rejection within 1 st Year Survival (%) (Transplants: April 1994 - June 2002) p = 0. 0002 ISHLT 2005 J Heart Lung Transplant 2005; 24: 945 -982

PEDIATRIC HEART TRANSPLANTATION Kaplan-Meier Survival Based on Rejection within 1 st Year Survival (%) (Transplants: January 1998 – June 2002) p = 0. 0001 ISHLT 2005 J Heart Lung Transplant 2005; 24: 945 -982

PEDIATRIC HEART TRANSPLANTS (1/1995 -6/2003) Risk Factors For 1 Year Mortality N=3, 014 ISHLT 2005 J Heart Lung Transplant 2005; 24: 945 -982

PEDIATRIC HEART TRANSPLANTS (1/1995 -6/2003) Borderline Significant Risk Factors For 1 Year Mortality N=3, 014 ISHLT 2005 J Heart Lung Transplant 2005; 24: 945 -982

PEDIATRIC HEART TRANSPLANTS (1/1995 -6/2003) Risk Factors for 1 Year Mortality ISHLT 2005 J Heart Lung Transplant 2005; 24: 945 -982

PEDIATRIC HEART TRANSPLANTS (1/1995 -6/2003) Risk Factors for 1 Year Mortality Donor Age ISHLT 2005 J Heart Lung Transplant 2005; 24: 945 -982

PEDIATRIC HEART TRANSPLANTS (1/1995 -6/2003) Risk Factors for 1 Year Mortality Pre-Transplant Bilirubin ISHLT 2005 J Heart Lung Transplant 2005; 24: 945 -982

PEDIATRIC HEART TRANSPLANTS (1/1995 -6/2003) Risk Factors for 1 Year Mortality Pre-Transplant Creatinine ISHLT 2005 J Heart Lung Transplant 2005; 24: 945 -982

PEDIATRIC HEART TRANSPLANTS (1/1995 -6/2003) Risk Factors for 1 Year Mortality Weight Ratio ISHLT 2005 J Heart Lung Transplant 2005; 24: 945 -982

PEDIATRIC HEART TRANSPLANTS (1/1995 -6/2003) Factors Not Significant for 1 Year Mortality Recipient Factors: IV inotropes, sternotomy, thoracotomy, history of malignancy, height, recent infection, age, PA pressure, cardiac output, pulmonary vascular resistance, PRA ISHLT 2005 J Heart Lung Transplant 2005; 24: 945 -982

PEDIATRIC HEART TRANSPLANTS (1/1995 -6/2003) Factors Not Significant for 1 Year Mortality Donor Factors: Gender, history of hypertension, height, clinical infection, cause of death, history of diabetes Transplant Factors: CMV mismatch, ABO identical/compatible, ischemia time, HLA mismatch, transplant center volume ISHLT 2005 J Heart Lung Transplant 2005; 24: 945 -982

PEDIATRIC HEART TRANSPLANTS (1/1995 -6/2003) 1 -Year Predicted Survival – Hypothetical Cases #1 and #2 ISHLT 2005 J Heart Lung Transplant 2005; 24: 945 -982

PEDIATRIC HEART TRANSPLANTS (1/1995 -6/2003) 1 -Year Predicted Survival – Hypothetical Case #3 ISHLT 2005 J Heart Lung Transplant 2005; 24: 945 -982

PEDIATRIC HEART TRANSPLANTS (1/1995 -6/2003) 1 -Year Predicted Survival – Hypothetical Cases #4 and #5 ISHLT 2005 J Heart Lung Transplant 2005; 24: 945 -982

PEDIATRIC HEART TRANSPLANTS (1/1995 -6/1999) Risk Factors For 5 Year Mortality N=1, 598 ISHLT 2005 J Heart Lung Transplant 2005; 24: 945 -982

PEDIATRIC HEART TRANSPLANTS (1/1995 -6/1999) Risk Factors for 5 Year Mortality ISHLT 2005 J Heart Lung Transplant 2005; 24: 945 -982

PEDIATRIC HEART TRANSPLANTS (1/1995 -6/1999) Risk Factors for 5 Year Mortality Pre-Transplant Recipient Weight ISHLT 2005 J Heart Lung Transplant 2005; 24: 945 -982

PEDIATRIC HEART TRANSPLANTS (1/1995 -6/1999) Risk Factors for 5 Year Mortality Pre-Transplant Creatinine ISHLT 2005 J Heart Lung Transplant 2005; 24: 945 -982

PEDIATRIC HEART TRANSPLANTS (1/1995 -6/1999) Factors Not Significant for 5 Year Mortality Recipient Factors: History of malignancy, recent infection, bilirubin, age, hospitalized at time of transplant, PRA, pulmonary vascular resistance, gender, PA pressures, cardiac output, sternotomy, height ISHLT 2005 J Heart Lung Transplant 2005; 24: 945 -982

PEDIATRIC HEART TRANSPLANTS (1/1995 -6/1999) Factors Not Significant for 5 Year Mortality Donor Factors: Cause of death, history of hypertension, weight, height, age Transplant Factors: Donor/recipient weight ratio, year of transplant, CMV mismatch, ischemia time, HLA mismatch, transplant center volume ISHLT 2005 J Heart Lung Transplant 2005; 24: 945 -982

PEDIATRIC HEART TRANSPLANTS (1/1995 -6/1999) 5 -Year Predicted Survival – Hypothetical Cases #1, 2 and 3 ISHLT 2005 J Heart Lung Transplant 2005; 24: 945 -982

PEDIATRIC HEART TRANSPLANTS (1/1995 -6/1999) 5 -Year Predicted Survival – Hypothetical Cases #4 and 5 ISHLT 2005 J Heart Lung Transplant 2005; 24: 945 -982

PEDIATRIC HEART TRANSPLANTS (1/1995 -6/1999) Risk Factors For 5 Year Mortality Conditional on 1 Year Survival N=1, 276 ISHLT 2005 J Heart Lung Transplant 2005; 24: 945 -982

PEDIATRIC HEART TRANSPLANTS (1/1995 -6/1999) Risk Factors For 5 Year Mortality Conditional on 1 Year Survival ISHLT 2005 J Heart Lung Transplant 2005; 24: 945 -982

PEDIATRIC HEART TRANSPLANTS (1/1995 -6/1999) Risk Factors For 5 Year Mortality Conditional on 1 Year Survival Recipient Weight ISHLT 2005 J Heart Lung Transplant 2005; 24: 945 -982

PEDIATRIC HEART TRANSPLANTS (1/1995 -6/1999) Risk Factors For 5 Year Mortality Conditional on 1 Year Survival Ischemia Time ISHLT 2005 J Heart Lung Transplant 2005; 24: 945 -982

PEDIATRIC HEART TRANSPLANTS (1/1995 -6/1999) Factors Not Significant for Conditional 5 Year Mortality Recipient Factors: History of malignancy, recent infection, hospitalized at time of transplant, bilirubin, creatinine, cardiac output, pulmonary vascular resistance, PRA, sternotomy, ventilator, VAD, age, PA pressures ISHLT 2005 J Heart Lung Transplant 2005; 24: 945 -982

PEDIATRIC HEART TRANSPLANTS (1/1995 -6/1999) Factors Not Significant for Conditional 5 Year Mortality Donor Factors: Cause of death, history of hypertension, weight, height, age, gender, clinical infection at donation Transplant Factors: Donor/recipient weight ratio, year of transplant, CMV mismatch, transplant center volume, induction use, treated for infection prior to discharge, dialysis prior to discharge ISHLT 2005 J Heart Lung Transplant 2005; 24: 945 -982

PEDIATRIC HEART TRANSPLANTS (1/1995 -6/1999) 5 -Year Predicted Survival Conditional on Survival to 1 Year – Hypothetical Case #1 ISHLT 2005 J Heart Lung Transplant 2005; 24: 945 -982

PEDIATRIC HEART TRANSPLANTS (1/1995 -6/1999) 5 -Year Predicted Survival Conditional on Survival to 1 Year – Hypothetical Case #2 ISHLT 2005 J Heart Lung Transplant 2005; 24: 945 -982

PEDIATRIC HEART TRANSPLANTS (1/1995 -6/1999) 5 -Year Predicted Survival Conditional on Survival to 1 Year – Hypothetical Case #3 ISHLT 2005 J Heart Lung Transplant 2005; 24: 945 -982

PEDIATRIC HEART TRANSPLANTS (1/1995 -6/1999) 5 -Year Predicted Survival Conditional on Survival to 1 Year – Hypothetical Case #4 ISHLT 2005 J Heart Lung Transplant 2005; 24: 945 -982

PEDIATRIC HEART TRANSPLANTS (1/1995 -6/1999) 5 -Year Predicted Survival Conditional on Survival to 1 Year – Hypothetical Case #5 ISHLT 2005 J Heart Lung Transplant 2005; 24: 945 -982

PEDIATRIC HEART RECIPIENTS Functional Status of Surviving Recipients (Follow-ups: April 1994 - June 2004) ISHLT 2005 J Heart Lung Transplant 2005; 24: 945 -982

PEDIATRIC HEART RECIPIENTS Rehospitalization Post-transplant of Surviving Recipients (Follow-ups: April 1994 - June 2004) ISHLT 2005 J Heart Lung Transplant 2005; 24: 945 -982

PEDIATRIC HEART RECIPIENTS % of Patients Induction Immunosuppression (Follow-ups: January 2001 - June 2004) ISHLT 2005 J Heart Lung Transplant 2005; 24: 945 -982

PEDIATRIC HEART RECIPIENTS Induction Immunosuppression (Follow-ups: January 2001 - June 2004) ISHLT 2005 J Heart Lung Transplant 2005; 24: 945 -982

PEDIATRIC HEART RECIPIENTS % of Patients Maintenance Immunosuppression at Time of Follow-up (Follow-ups: January 2001 - June 2004) NOTE: Different patients are analyzed in Year 1 and Year 5 ISHLT 2005 J Heart Lung Transplant 2005; 24: 945 -982

PEDIATRIC HEART RECIPIENTS % of Patients Maintenance Immunosuppression Drug Combinations at Time of Follow-up (Follow-ups: January 2001 - June 2004) ISHLT NOTE: Different patients are analyzed in Year 1 and Year 5 2005 J Heart Lung Transplant 2005; 24: 945 -982

PERCENTAGE OF PEDIATRIC HEART TRANSPLANT RECIPIENTS TREATED FOR REJECTION IN 1 ST YEAR % treated for rejection within 1 year Stratified by Induction (Transplants: January 2000 - June 2003) No within age group or gender comparisons were significant. ISHLT 2005 J Heart Lung Transplant 2005; 24: 945 -982

NUMBER OF REJECTION EPISODES FOR PEDIATRIC HEART TRANSPLANT RECIPIENTS TREATED FOR REJECTION IN 1 ST YEAR Average number of rejection episodes Stratified by Induction (Transplants: January 2000 - June 2003) ISHLT 2005 J Heart Lung Transplant 2005; 24: 945 -982

PERCENTAGE OF PEDIATRIC HEART TRANSPLANT RECIPIENTS TREATED FOR REJECTION IN 1 ST YEAR % treated for rejection within 1 year Stratified by Type of Induction (Transplants: January 2000 - June 2003) Overall: No induction vs. OKT 3 (p = 0. 0003); polyclonal vs. OKT 3 (p = 0. 0017); IL 2 vs. OKT 3 (p = 0. 0010). 1 -10: No induction vs. polyclonal (p = 0. 04); 11 -17: No induction vs. OKT 3 (p = 0. 003); polyclonal vs. OKT 3 (p = 0. 007); IL 2 R vs. OKT 3 (p = 0. 002) Female: No induction vs. OKT 3 (p = 0. 003); polyclonal vs. OKT 3 (p = 0. 01); IL 2 R vs. OTK 3 (p = 0. 03) Male: No induction vs. OKT 3 (p=0. 03); polyclonal vs. OKT 3 (p < 0. 05); IL 2 R vs. OKT 3 (p = 0. 01) ISHLT 2005 J Heart Lung Transplant 2005; 24: 945 -982

NUMBER OF REJECTION EPISODES FOR PEDIATRIC HEART TRANSPLANT RECIPIENTS TREATED FOR REJECTION IN 1 ST YEAR Average number of rejection episodes Stratified by Type of Induction (Transplants: January 2000 - June 2003) ISHLT 2005 J Heart Lung Transplant 2005; 24: 945 -982

PERCENTAGE OF PEDIATRIC HEART TRANSPLANT RECIPIENTS TREATED FOR REJECTION IN 1 ST YEAR % treated for rejection within 1 year Stratified by Maintenance Immunosuppression and Induction (Transplants: January 2000 - June 2003) Overall: Cy. A + no induction vs. TAC + no induction: p = 0. 0045; Cy. A + induction vs. TAC + induction: p = 0. 0188; Cy. A + induction vs. TAC + no induction: p = 0. 0204; Cy. A + no induction vs. TAC +induction: p = 0. 0071; 1 -10 years: Cy. A + no induction vs. TAC + no induction: p = 0. 0313; Cy. A + induction vs. TAC + induction: p = 0. 0144; Cy. A + induction vs. TAC + no induction: p = 0. 0011. Female: Cy. A + no induction vs. TAC + no induction: p=0. 008; Cy. A + induction vs. TAC + induction: p = 0. 0163; Cy. A + induction vs. TAC + no induction: p = 0. 0166; Cy. A + no induction vs. TAC + induction: p = 0. 0097. No other age group or gender differences were significant. ISHLT 2005 J Heart Lung Transplant 2005; 24: 945 -982

NUMBER OF REJECTION EPISODES FOR PEDIATRIC HEART TRANSPLANT RECIPIENTS TREATED FOR REJECTION IN 1 ST YEAR Stratified by Maintenance Immunosuppression and Induction Average number of rejection episodes (Transplants: January 2000 - June 2003) ISHLT 2005 J Heart Lung Transplant 2005; 24: 945 -982

PERCENTAGE OF PEDIATRIC HEART TRANSPLANT RECIPIENTS TREATED FOR REJECTION IN 1 ST YEAR % treated for rejection within 1 year Stratified by Maintenance Immunosuppression (Transplants: January 2000 - June 2003) Overall: Cy. A+MMF vs. TAC+MMF (p = 0. 0071); Cy. A +MMF vs. TAC + AZA (p = 0. 0018); Cy. A + AZA vs. TAC + MMF (p = 0. 0026); Cy. A + AZA vs. TAC + AZA (p = 0. 0009). <1: Cy. A + MMF vs. TAC + MMF ( p = 0. 03); Cy. A + AZA vs. TAC + MMF (p = 0. 005). 1 -10: Cya + MMF vs. TAC + AZA (p = 0. 005); Cy. A + AZA vs. TAC + AZA (p = 0. 004). 11 -17: Cy. A + AZA vs. TAC + MMF (p = 0. 01). Female: Cy. A + MMF vs. TAC + AZA (p = 0. 002); Cy. A + AZA vs. TAC + MMF (p = 0. 01); Cy. A + AZA vs. TAC + AZA (p=0. 0006); TAC + MMF vs. TAC + AZA (p = 0. 03). Male: Cy. A + MMF vs. TAC + MMF (p < 0. 05) ISHLT 2005 J Heart Lung Transplant 2005; 24: 945 -982

NUMBER OF REJECTION EPISODES FOR PEDIATRIC HEART TRANSPLANT RECIPIENTS TREATED FOR REJECTION IN 1 ST YEAR Average number of rejection episodes Stratified by Maintenance Immunosuppression (Transplants: January 2000 - June 2003) <1 years: Cy. A + AZA vs. TAC + MMF (p=0. 004). No other age group or gender comparisons were significant. ISHLT 2005 J Heart Lung Transplant 2005; 24: 945 -982

PERCENTAGE OF PEDIATRIC HEART TRANSPLANT RECIPIENTS TREATED FOR REJECTION IN 1 ST YEAR Stratified by Tacrolimus vs. Cyclosporine Use at Discharge % treated for rejection within 1 year Conditional on Survival to 14 Days (Transplants: January 2000 - June 2003) <1: Cy. A vs. TAC (p = 0. 0156) 1 -10: Cy. A vs. TAC (p = 0. 0013) Females: Cy. A vs. TAC (p = 0. 0001) ISHLT 2005 J Heart Lung Transplant 2005; 24: 945 -982

NUMBER OF REJECTION EPISODES FOR PEDIATRIC HEART TRANSPLANT RECIPIENTS TREATED FOR REJECTION IN 1 ST YEAR Stratified by Tacrolimus vs. Cyclosporine Use at Discharge Average number of rejection episodes Conditional on Survival to 14 Days (Transplants: January 2000 - June 2003) ISHLT 2005 J Heart Lung Transplant 2005; 24: 945 -982

POST-HEART TRANSPLANT MORBIDITY FOR PEDIATRICS Cumulative Prevalence in Survivors within 1 Year Post-Transplant (Follow-ups: April 1994 - June 2004) ISHLT 2005 J Heart Lung Transplant 2005; 24: 945 -982

POST-HEART TRANSPLANT MORBIDITY FOR PEDIATRICS Cumulative Prevalence in Survivors within 5 Years Post-Transplant (Follow-ups: April 1994 - June 2004) ISHLT 2005 J Heart Lung Transplant 2005; 24: 945 -982

POST-HEART TRANSPLANT MORBIDITY FOR PEDIATRICS Cumulative Prevalence in Survivors within 7 Years Post-Transplant (Follow-ups: April 1994 - June 2004) ISHLT 2005 J Heart Lung Transplant 2005; 24: 945 -982

FREEDOM FROM CORONARY ARTERY VASCULOPATHY % Freedom from CAV For Pediatric Heart Recipients (Follow-ups: April 1994 - June 2004) ISHLT 2005 J Heart Lung Transplant 2005; 24: 945 -982

FREEDOM FROM CORONARY ARTERY VASCULOPATHY For Pediatric Heart Recipients (Follow-ups: April 1994 - June 2004) % Freedom from CAV Stratified by Induction p = 0. 43 ISHLT 2005 J Heart Lung Transplant 2005; 24: 945 -982

FREEDOM FROM CORONARY ARTERY VASCULOPATHY For Pediatric Heart Recipients (Follow-ups: April 1994 - June 2004) % Freedom from CAV Stratified by Age Group ISHLT 2005 J Heart Lung Transplant 2005; 24: 945 -982

GRAFT SURVIVAL FOLLOWING REPORT OF CORONARY ARTERY VASCULOPATHY Survival since Report of CAV (%) For Pediatric Heart Recipients (Follow-ups: April 1994 - June 2004) Stratified by Age Group ISHLT 2005 J Heart Lung Transplant 2005; 24: 945 -982

% Freedom from Severe Renal Dysfunction FREEDOM FROM SEVERE RENAL DYSFUNCTION* For Pediatric Heart Recipients (Follow-ups: April 1994 - June 2004) * Severe renal dysfunction = Creatinine > 2. 5 mg/dl, dialysis or renal transplant ISHLT 2005 J Heart Lung Transplant 2005; 24: 945 -982

MALIGNANCY POST-HEART TRANSPLANTATION FOR PEDIATRICS Cumulative Prevalence in Survivors (Follow-ups: April 1994 - June 2004) Malignancy/Type 1 -Year Survivors No Malignancy 45 (2. 0%) 31 (4. 1%) 24 (6. 2%) Lymph 41 27 Other 3 3 Type Not Reported 1 Other types: Ewings, Large cell lymphoma ISHLT 7 -Year Survivors 2230 (98. 0%) 716 (95. 9%) 365 (93. 8%) Malignancy (all types combined) Malignancy Type 5 -Year Survivors 2005 J Heart Lung Transplant 2005; 24: 945 -982 22

FREEDOM FROM MALIGNANCY % Freedom from Malignancy For Pediatric Heart Recipients (Follow-ups: April 1994 - June 2004) ISHLT 2005 J Heart Lung Transplant 2005; 24: 945 -982

PEDIATRIC HEART TRANSPLANTATION Kaplan-Meier Survival Based on Prednisone Use Survival (%) (Transplants: April 1994 - June 2003) p = 0. 0006 ISHLT 2005 J Heart Lung Transplant 2005; 24: 945 -982

PEDIATRIC HEART TRANSPLANTATION Kaplan-Meier Survival Based on Prednisone Use Survival (%) (Transplants: January 1998 – June 2003) p = 0. 009 ISHLT 2005 J Heart Lung Transplant 2005; 24: 945 -982

PEDIATRIC HEART TRANSPLANTATION Kaplan-Meier Survival by Induction Group (Transplants: January 2000 – June 2003) Conditional on Survival to 14 Days Survival (%) No comparisons were statistically significant. ISHLT 2005 J Heart Lung Transplant 2005; 24: 945 -982

PEDIATRIC HEART TRANSPLANTATION Kaplan-Meier Survival by Induction Group (Transplants: January 2000 – June 2003) Conditional on Survival to 14 Days Survival (%) Age: < 1 Year ISHLT 2005 J Heart Lung Transplant 2005; 24: 945 -982

PEDIATRIC HEART TRANSPLANTATION Survival (%) Kaplan-Meier Survival by Induction Group (Transplants: January 2000 – June 2003) Conditional on Survival to 14 Days Age: 1 -10 Years ISHLT 2005 J Heart Lung Transplant 2005; 24: 945 -982

PEDIATRIC HEART TRANSPLANTATION Kaplan-Meier Survival by Induction Group (Transplants: January 2000 – June 2003) Survival (%) Conditional on Survival to 14 Days Age: 11 -17 Years ISHLT 2005 J Heart Lung Transplant 2005; 24: 945 -982

PEDIATRIC HEART TRANSPLANTATION Survival (%) Kaplan-Meier Survival Stratified by Tacrolimus vs. Cyclosporine Use at Discharge (Transplants: January 1998 - June 2003) Conditional on Survival to 14 Days ISHLT 2005 J Heart Lung Transplant 2005; 24: 945 -982

PEDIATRIC HEART RECIPIENTS Incidence of Hypertension between 1 and 3 Years (Transplants: April 1993 - June 2001) Maintenance Immunosuppression at discharge and 1 year % HTN reported between 1 and 3 years P-value For Patients on drug For Patients not on drug Azathioprine 21. 6% 22. 1% 0. 9 Cyclosporine 20. 5% 21. 4% 0. 8 MMF 19. 9% 21. 0% 0. 8 Prednisone 28. 9% 6. 6% <0. 0001 Rapamycin . 20. 6% Tacrolimus 24. 8% 19. 5% 0. 2 ISHLT 2005 J Heart Lung Transplant 2005; 24: 945 -982

PEDIATRIC HEART RECIPIENTS Relationship of Rejection and Coronary Artery Vasculopathy (Follow-ups: April 1994 – June 2004) Rejection Reported CAV between 1 st During 1 st and 3 rd years Year post-transplant Reported CAV between 3 rd and 5 th years post-transplant Yes No All Yes 36 8. 1% 408 91. 9% 444 100% 12 6. 5% 174 93. 5% 186 100% No 13 3. 0% 420 97. 0% 433 100% 9 4. 6% 188 95. 4% 197 100% p = 0. 001 p = 0. 4185 ISHLT 2005 NOTE: Only those recipients without CAV prior to 3 years were included in the last set of columns J Heart Lung Transplant 2005; 24: 945 -982

PEDIATRIC HEART RECIPIENTS Growth Following Transplantation: Height Stratified by Prednisone Use at Discharge and at 1 Year ISHLT 2005 J Heart Lung Transplant 2005; 24: 945 -982

PEDIATRIC HEART RECIPIENTS Growth Following Transplantation: Weight Stratified by Prednisone Use at Discharge and at 1 Year ISHLT 2005 J Heart Lung Transplant 2005; 24: 945 -982

PEDIATRIC HEART TRANSPLANT RECIPIENTS: Cause of Death (Deaths: January 1992 - June 2004) CAUSE OF DEATH 0 -30 Days 31 Days - 1 Year >1 Year - 3 Years >3 Years - 5 Years >5 Years (N (N = 335) (N = 281) (N = 198) (N = 139) = 252) CORONARY ARTERY VASCULOPATHY 3 (0. 9%) 26 (9. 3%) 36 (18. 2%) 52 (37. 4%) 72 (28. 6%) ACUTE REJECTION 27 (8. 1%) 76 (27. 0%) 54 (27. 3%) 18 (12. 9%) 32 (12. 7%) LYMPHOMA 6 (2. 1%) 10 (5. 1%) 3 (2. 2%) 21 (8. 3%) MALIGNANCY, OTHER 4 (1. 4%) 2 (1. 0%) 1 (0. 7%) 9 (3. 6%) 1 (0. 3%) 7 (2. 5%) 1 (0. 5%) INFECTION, NON-CMV 47 (14. 0%) 46 (16. 4%) 17 (8. 6%) 6 (4. 3%) 16 (6. 3%) PRIMARY FAILURE 58 (17. 3%) 11 (3. 9%) 6 (3. 0%) 8 (5. 8%) 12 (4. 8%) GRAFT FAILURE 79 (23. 6%) 31 (11. 0%) 35 (17. 7%) 27 (19. 4%) 49 (19. 4%) TECHNICAL 21 (6. 3%) 2 (0. 7%) 2 (1. 0%) 1 (0. 7%) 1 (0. 4%) OTHER 15 (4. 5%) 16 (5. 7%) 16 (8. 1%) 14 (10. 1%) 24 (9. 5%) MULTIPLE ORGAN FAILURE 36 (10. 7%) 29 (10. 3%) 3 (1. 5%) 2 (1. 4%) 6 (2. 4%) RENAL FAILURE 1 (0. 3%) 4 (1. 4%) 1 (0. 5%) PULMONARY 24 (7. 2%) 16 (5. 7%) 9 (4. 5%) 6 (4. 3%) 7 (2. 8%) CEREBROVASCULAR 23 (6. 9%) 7 (2. 5%) 6 (3. 0%) 1 (0. 7%) 3 (1. 2%) CMV ISHLT 2005 J Heart Lung Transplant 2005; 24: 945 -982